欧美成一级-欧美成在人线a免费-欧美传媒影-欧美大逼逼-欧美大成色www永久网站婷-欧美大胆a级视频

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Enhanced T Cell Platforms

Enhanced T Cell Platforms (HyperTCell ®), including HyperCART® , are mainly to solve the global highlighted problem in solid tumor therapy through genetic modification of T cells. HyperCART® takes improving the clinical efficacy of CAR-T in solid tumors as its core purpose. Based on the concept of synthetic biology, HyperCART® adopts efficient gene delivery system to target tumor cells specifically, reverse the immuno suppressive state and improve the predicament of difficult infiltration and poor efficacy of traditional CAR-T in solid tumor therapy. 


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 国产精品无码免费视频二三区 | 国产一级黄色视频免费看 | 欧美色在线一区精品 | 亚洲四虎永久在线播放 | 色噜噜国产精品 | 国产一级a免费无码播放 | 日韩一区二区三区四区在线 | 国产精品另类激情久久久免 | 国产欧美视频一区二区三区 | 亚洲国产精品综合久久网各 | 日本不卡高字幕在线2025 | 欧美午夜精品一区二区蜜桃 | 国产成人亚洲日韩欧美久久 | 国产ts在线播放 | 九七电影网手机版 | 2025在线精品自偷自 | 亚洲av日韩 | 日韩国产免费 | 国产一区一二区高清不卡 | 日韩黄色毛片一级 | 99国产在线精品国自产在 | 97理论三级九七午夜在线观看 | 精品女同一区二区三区在线观看 | 亚洲欧美日韩在线码 | 亚洲最大无码的黄色网站 | 欧美一级免费在线观看 | 国产日产欧产精品网站 | 91精品国产 | 亚洲精品欧美 | 中文字幕在线成人免费看 | 国产麻花豆剧传媒 | 欧美一级特黄大片做受在线观看 | 蜜桃视频一区二区在线观看 | 国产三级ⅴ在在线观看 | 夜夜操b天天干天天操天天 夜夜操天天操 | 人人婷婷人人澡人人爽 | 人人天天夜夜 | 欧美激情亚洲一区中文字幕 | 中文字幕无码视频 | 制服丝袜人妻中文字幕在线 | 久久久91一区二区三区 |